1 April 2024 false No description of principal activity Taxfiler 2024.6 08872774business:PrivateLimitedCompanyLtd2024-04-012025-03-31 088727742024-03-31 088727742024-04-012025-03-31 08872774business:AuditExempt-NoAccountantsReport2024-04-012025-03-31 08872774business:FilletedAccounts2024-04-012025-03-31 088727742025-03-31 08872774business:Director12024-04-012025-03-31 08872774business:Director22024-04-012025-03-31 08872774business:RegisteredOffice2024-04-012025-03-31 088727742024-03-31 08872774core:WithinOneYear2025-03-31 08872774core:WithinOneYear2024-03-31 08872774core:AfterOneYear2025-03-31 08872774core:AfterOneYear2024-03-31 08872774core:ShareCapitalcore:PreviouslyStatedAmount2025-03-31 08872774core:ShareCapitalcore:PreviouslyStatedAmount2024-03-31 08872774core:RetainedEarningsAccumulatedLossescore:PreviouslyStatedAmount2025-03-31 08872774core:RetainedEarningsAccumulatedLossescore:PreviouslyStatedAmount2024-03-31 08872774core:PreviouslyStatedAmount2025-03-31 08872774core:PreviouslyStatedAmount2024-03-31 08872774business:SmallEntities2024-04-012025-03-31 08872774countries:EnglandWales2024-04-012025-03-31 08872774core:ComputerEquipment2024-04-012025-03-31 08872774core:LandBuildings2024-03-31 08872774core:ComputerEquipment2024-03-31 08872774core:LandBuildings2025-03-31 08872774core:ComputerEquipment2025-03-31 08872774core:LandBuildings2024-04-012025-03-31 088727742023-04-012024-03-31 iso4217:GBP xbrli:pure
Company Registration No. 08872774 (England and Wales)
Sapphire Clinical Research Ltd Unaudited accounts for the year ended 31 March 2025
Sapphire Clinical Research Ltd Unaudited accounts Contents
Page
Company information
3
Statement of financial position
4
Notes to the accounts
5
- 2 -
Sapphire Clinical Research Ltd Company Information for the year ended 31 March 2025
Directors
Dr Michelle Court Stephen Gunnigle
Company Number
08872774 (England and Wales)
Registered Office
The Barn Cross Lane Weston Underwood Olney Buckinghamshire MK46 5LD England
- 3 -
Sapphire Clinical Research Ltd Statement of financial position as at 31 March 2025
2025 
2024 
Notes
£ 
£ 
Fixed assets
Tangible assets
4
248,545 
248,734 
Current assets
Debtors
5
- 
75 
Cash at bank and in hand
15,330 
5,417 
15,330 
5,492 
Creditors: amounts falling due within one year
6
(2,417)
(1,969)
Net current assets
12,913 
3,523 
Total assets less current liabilities
261,458 
252,257 
Creditors: amounts falling due after more than one year
7
(106,223)
(105,948)
Net assets
155,235 
146,309 
Capital and reserves
Called up share capital
1 
1 
Profit and loss account
155,234 
146,308 
Shareholders' funds
155,235 
146,309 
For the year ending 31 March 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with the provisions of FRS 102 Section 1A - Small Entities. The profit and loss account has not been delivered to the Registrar of Companies.
The financial statements were approved by the Board of Directors and authorised for issue on 2 December 2025 and were signed on its behalf by
Dr Michelle Court Director Company Registration No. 08872774
- 4 -
Sapphire Clinical Research Ltd Notes to the Accounts for the year ended 31 March 2025
1
Statutory information
Sapphire Clinical Research Ltd is a private company, limited by shares, registered in England and Wales, registration number 08872774. The registered office is The Barn, Cross Lane, Weston Underwood, Olney, Buckinghamshire, MK46 5LD, England.
2
Compliance with accounting standards
The accounts have been prepared in accordance with the provisions of FRS 102 Section 1A Small Entities. There were no material departures from that standard.
3
Accounting policies
The principal accounting policies adopted in the preparation of the financial statements are set out below and have remained unchanged from the previous year, and also have been consistently applied within the same accounts.
Basis of preparation
The accounts have been prepared under the historical cost convention as modified by the revaluation of certain fixed assets.
Presentation currency
The accounts are presented in £ sterling.
Tangible fixed assets and depreciation
Tangible assets are included at cost less depreciation and impairment. Depreciation has been provided at the following rates in order to write off the assets over their estimated useful lives:
Computer equipment
10% Straight Line
4
Tangible fixed assets
Land & buildings 
Computer equipment 
Total 
£ 
£ 
£ 
Cost or valuation
At cost 
At cost 
At 1 April 2024
248,405 
2,571 
250,976 
At 31 March 2025
248,405 
2,571 
250,976 
Depreciation
At 1 April 2024
- 
2,242 
2,242 
Charge for the year
- 
189 
189 
At 31 March 2025
- 
2,431 
2,431 
Net book value
At 31 March 2025
248,405 
140 
248,545 
At 31 March 2024
248,405 
329 
248,734 
5
Debtors
2025 
2024 
£ 
£ 
Amounts falling due within one year
Other debtors
- 
75 
- 5 -
Sapphire Clinical Research Ltd Notes to the Accounts for the year ended 31 March 2025
6
Creditors: amounts falling due within one year
2025 
2024 
£ 
£ 
Taxes and social security
1,850 
- 
Other creditors
567 
567 
Accruals
- 
1,402 
2,417 
1,969 
7
Creditors: amounts falling due after more than one year
2025 
2024 
£ 
£ 
Loans from directors
106,223 
105,948 
8
Average number of employees
During the year the average number of employees was 0 (2024: 0).
- 6 -